ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis' blockbuster-to-be Mayzent helps MS patients think faster
May 09, 2019Novartis’ newly approved multiple sclerosis therapy Mayzent has already shown an ability to cut disability progression and forestall brain shrinkage in patients with the secondary progressive form of the disease (SPMS). Now, it has more data to back its c -
AbbVie shakes up psoriasis field with blockbuster-to-be newcomer Skyrizi
April 25, 2019Move over, Johnson & Johnson—AbbVie just joined the party with a direct competitor to Tremfya, and analysts say it might just be best-in-class.
Pharma Sources Insight January 2025
